Not one comment in favor of the merger...Given that there was no mention that CZO's main client has returned in the Information Circular(that I'm aware of) and that CZO had ~$11 million cash at the end of September how much cash will be left by the vote? That will be about 5 1/2 months. They never mentioned the current cash in the Information Circular which could be an issue. Since September 30, 2023 CZO needed cash to cover the costs of the proposed merger, the ramp up of the avenanthramide clinical trial, and the simultaneous 5X and 10X scale-up of PGX including with Natex. The additional studies with the Angiogenesis Foundation were also said to be ongoing and they may have begun the toxicology study for the fibrosis drug. There's also a $500,000 breakup fee for the merger but I'm not sure of the conditions. How much cash will CZO have left by the vote? People here like to talk about delays so what if there are delays with PGX scale-up? Are people proposing a financing with warrants and if shareholders have not been willing to listen to the universal recommendation of the Board of Directors and Special Committee and derail this deal who will want to do a financing? The costs of trying to put this merger together have been significant are people suggesting another round or costs and if shareholders don't listen to the Board could that make deal shopping risky? Will the company be in need of additional capital to move things forward and in the penalty box due to the failed deal? On the other hand the AEZS deal provides financing without warrants and fully finances CZO's near term revenue generating prospects. CZO could get to work after the merger closes without further delay.